Business, energy, technology, markets and global industry news from Business News Today

Montgomery–Åsberg Depression Rating Scale

PharmaDeviceNews Montgomery–Åsberg Depression Rating Scale
Infographic highlighting Alkermes’ 180-patient Phase 2 ALKS 7290 depression trial, featuring a neural brain illustration and key details about orexin activation alongside antidepressants and safety evaluation.
Pharma & Biotech

Alkermes launches 180-patient Phase 2 ALKS 7290 trial testing orexin activation in major depression

Alkermes starts a 180-patient Phase 2 ALKS 7290 depression trial, testing orexin activation alongside antidepressants and assessing safety.

Read More